Contineum Therapeutics Appoints New CMO & CSO
Ticker: CTNM · Form: 8-K · Filed: May 20, 2024 · CIK: 1855175
| Field | Detail |
|---|---|
| Company | Contineum Therapeutics, Inc. (CTNM) |
| Form Type | 8-K |
| Filed Date | May 20, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, personnel
TL;DR
Contineum beefs up leadership with new CMO & CSO appointments.
AI Summary
Contineum Therapeutics, Inc. announced on May 20, 2024, the appointment of Dr. Jonathan Leipsic as Chief Medical Officer and Dr. David E. R. Brown as Chief Scientific Officer. The company also disclosed compensatory arrangements for these key officers, including base salaries and potential equity awards, as part of its ongoing development of novel therapeutics.
Why It Matters
The appointment of experienced Chief Medical and Scientific Officers is crucial for advancing Contineum's drug development pipeline and attracting further investment.
Risk Assessment
Risk Level: medium — The company is in the pharmaceutical development stage, which inherently carries high risks related to clinical trials, regulatory approvals, and market adoption.
Key Numbers
- May 20, 2024 — Report Date (Date of earliest event reported)
Key Players & Entities
- Contineum Therapeutics, Inc. (company) — Registrant
- Jonathan Leipsic (person) — Appointed Chief Medical Officer
- David E. R. Brown (person) — Appointed Chief Scientific Officer
- Pipeline Therapeutics, Inc. (company) — Former Company Name
FAQ
Who has been appointed as the new Chief Medical Officer?
Dr. Jonathan Leipsic has been appointed as the Chief Medical Officer.
Who is the new Chief Scientific Officer?
Dr. David E. R. Brown has been appointed as the Chief Scientific Officer.
What is the company's former name?
The company's former name was Pipeline Therapeutics, Inc.
When was the name change from Pipeline Therapeutics, Inc. to Contineum Therapeutics, Inc.?
The date of the name change was April 5, 2021.
What is the principal executive office address?
The principal executive office is located at 10578 Science Center Drive, Suite 200, San Diego, California 92121.
Filing Stats: 958 words · 4 min read · ~3 pages · Grade level 10.1 · Accepted 2024-05-20 16:09:10
Key Financial Figures
- $0.001 — tered Class A Common Stock , par value $0.001 per share CTNM The Nasdaq Global Mar
Filing Documents
- cont20240420_8k.htm (8-K) — 30KB
- 0001437749-24-017651.txt ( ) — 164KB
- noticker-20240520.xsd (EX-101.SCH) — 3KB
- noticker-20240520_def.xml (EX-101.DEF) — 12KB
- noticker-20240520_lab.xml (EX-101.LAB) — 15KB
- noticker-20240520_pre.xml (EX-101.PRE) — 12KB
- cont20240420_8k_htm.xml (XML) — 3KB
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. Exhibit No. Description 10.1 Form of Indemnity Agreement (incorporated by reference to Exhibit 10.1 to the Registrant's Amended Registration Statement on Form S-1/A (File No. 333-278003) filed with the Securities and Exchange Commission on April 1, 2024). 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: May 20, 2024 CONTINEUM THERAPEUTICS, INC. By: /s/ Peter Slover Peter Slover Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer)